Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review

@article{Bellantuono2007SerotoninRI,
  title={Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review},
  author={Cesario Bellantuono and Giovanni Migliarese and Salvatore Gentile},
  journal={Human Psychopharmacology: Clinical and Experimental},
  year={2007},
  volume={22}
}
To review studies conducted to establish the risk of major congenital malformations in women exposed to serotonin reuptake inhibitors (SRIs) during the first trimester of pregnancy. 
Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects
  • S. Gentile
  • Medicine
  • Acta psychiatrica Scandinavica
  • 2011
TLDR
It is necessary to select serotonin reuptake inhibitor exposure during early pregnancy to reduce the risk of birth defects in women with high-risk pregnancies, according to Gentile S. Expand
Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms
  • S. Gentile
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2015
TLDR
A cautious approach of using SSRI during pregnancy only in the case of major depressive episodes should be applied, and this risk should be balanced against the risks associated with the worsening of depressive symptoms. Expand
Prenatal exposure to serotonin reuptake inhibitors: a case report
TLDR
Two premature twins were born to a woman who had used paroxetine during pregnancy for an anxiety-depression disorder, where they showed prolonged RDS, cardiovascular malformations, and facial dysmorphisms, which partially disappeared during the following weeks, although alterations of tone persisted even at discharge. Expand
Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences
SUMMARY Aim – To review studies conducted to establish the risk of spontaneous abortion (SA) in women exposed to anti-depressant drugs (ADs) during early pregnancy. Methods – By using differentExpand
Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
TLDR
Pregnant women who require treatment for depression and their physicians often face a difficult choice regarding the use of SSRIs, as the possibility of such functional abnormalities is an additional concern. Expand
Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?
TLDR
This review describes possible relationship between SSRIs pharmacogenetics and different neonatal outcomes and summarizes the current pharmacogenetic inquiries in relation to maternal-foetal environment. Expand
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update
TLDR
In pregnant or lactating women who require a pharmacological treatment, SSRIs can still be considered as appropriate when effective as the abundant data support their relative safety. Expand
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence
TLDR
In women suffering from major depression and responding to a pharmacological treatment, introduction or continuation of an SSRI should be encouraged in order to prevent maternal complications and to preserve maternal–infant bonding. Expand
More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation
TLDR
Clinical questions are presented considering the available literature on safety of psychotropics in pregnancy and lactation and the application of these recommendations into clinical practice appears to be complex. Expand
Critical determinants of the risk-benefit assessment of antidepressants in pregnancy : pharmacokinetic, safety and economic considerations.
TLDR
Factors that should be included in these analyses include the pharmacokinetics and pharmacodynamics of antidepressants in pregnancy and their maternal and fetal safety. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 58 REFERENCES
Newer antidepressants in pregnancy and rates of major malformations: a meta‐analysis of prospective comparative studies
TLDR
A large number of women of childbearing age suffer from depression and relatively little is known about the safety of antidepressant use during pregnancy, so it is necessary to select patients suitable for antidepressant use. Expand
Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials.
TLDR
The results find that SRIs do not increase the risk of major, cardiovascular and minor malformations but do increase therisk of spontaneous abortion significantly. Expand
Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
TLDR
The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses. Expand
Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy
TLDR
Use of SSRIs during pregnancy is not independently associated with increased risk of adverse perinatal outcome other than need for treatment in neonatal special or intensive care unit. Expand
Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.
TLDR
The use of selective serotonin reuptake inhibitors in pregnancy may increase the risks of low birth weight, preterm birth, fetal death, and seizures. Expand
Treatment with Selective Serotonin Reuptake Inhibitors in the Third Trimester of Pregnancy
TLDR
The interpretation of the current literature suggests that the risk of not receiving adequate antidepressant treatment in the third trimester when indicated outweighs the risks of adverse events in the infant, and adequate pharmacological treatment should not be withheld from a depressed pregnant woman in late pregnancy. Expand
Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations
TLDR
An increased risk of congenital malformations after exposure to SSRIs in early pregnancy is found, although it is unclear whether the effects were causal or due to factors related to the underlying disease. Expand
Safety of selective serotonin reuptake inhibitors in pregnancy.
TLDR
The review tries to clarify the blurred aspects of the use of SSRI during pregnancy and to give sensible and up-to-dated guidelines for the treatment of psychiatric disorders with SSRIs during pregnancy. Expand
Citalopram in pregnancy and lactation
TLDR
The aim of this study was to examine the efficacy and safety of citalopram in relation to concentrations of cITALopram and its metabolites during pregnancy and lactation. Expand
Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies
TLDR
The use of fluoxetine during the first trimester of pregnancy is not associated with measurable teratogenic effects in human and power analysis indicates that 26 controlled studies of similar size, would be required, to reverse this finding. Expand
...
1
2
3
4
5
...